R. Maini, S. Clair, E. Breedveld, F. Furst, D. Kalden et al., Infliximab (chimeric anti-tumour necrosis factor ?? monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, The Lancet, vol.354, issue.9194, pp.1932-1939, 1999.
DOI : 10.1016/S0140-6736(99)05246-0

S. Clair, E. Wagner, C. Fasanmade, A. Wang, B. Schaible et al., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.49, issue.6, pp.1451-1459, 2002.
DOI : 10.1002/art.10302

G. Wolbink, A. Voskuyl, W. Lems, E. De-groot, M. Nurmohamed et al., Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-707, 2005.
DOI : 10.1136/ard.2004.030452

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3789, 2006.
DOI : 10.1002/art.22214

M. Rahman, I. Strusberg, P. Geusens, A. Berman, D. Yocum et al., Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1233-1238, 2007.
DOI : 10.1136/ard.2006.065995

S. Mori, A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy, Modern Rheumatology, vol.73, issue.2, pp.83-91, 2007.
DOI : 10.1002/art.20568

C. Miow-lin, D. Ducourau, E. Mulleman, D. Emond, P. Ternant et al., Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis, Ann Rheum Dis, issue.2, pp.67-177, 2008.

P. Durez, F. Bosch, . Van-den, L. Corluy, E. Veys et al., A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study, Rheumatology, vol.44, issue.4, pp.465-468, 2005.
DOI : 10.1093/rheumatology/keh494

E. Collantes-estevez, M. Muñoz-villanueva, P. Zarco, J. Torre-alonso, J. Gratacós et al., Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study, Rheumatology, vol.44, issue.12, pp.1555-1558, 2005.
DOI : 10.1093/rheumatology/kei085

B. Fautrel, T. Pham, G. Mouterde, L. Loet, X. Goupille et al., Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with rheumatoid arthritis, Joint Bone Spine, vol.74, issue.6, pp.627-637, 2007.
DOI : 10.1016/j.jbspin.2007.10.001

D. Ternant, D. Mulleman, D. Degenne, S. Willot, J. Guillaumin et al., An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab, Therapeutic Drug Monitoring, vol.28, issue.2, pp.169-174, 2006.
DOI : 10.1097/01.ftd.0000189901.08684.4b

F. Baert, M. Noman, S. Vermeire, G. Van-assche, D. Haens et al., Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-608, 2003.
DOI : 10.1056/NEJMoa020888

F. Cornillie, D. Shealy, D. 'haens, G. Geboes, K. Van-assche et al., Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.94, issue.4, pp.463-473, 2001.
DOI : 10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K

G. Wolbink, M. Vis, W. Lems, A. Voskuyl, E. De-groot et al., Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.86, issue.3, pp.711-715, 2006.
DOI : 10.1002/art.21671

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-2285, 2006.
DOI : 10.1001/jama.295.19.2275

E. Aikawa, N. De-carvalho, J. , A. A. Silva, C. Bonfa et al., Immunogenicity of anti-TNF-alpha agents in autoimmune diseases, Clin Rev Allergy Immunol, 2009.

T. Radstake, M. Svenson, A. Eijsbouts, F. Hoogen, . Van-den et al., Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.1739-1745, 2009.
DOI : 10.1136/ard.2008.092833

Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson et al., Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.26, issue.suppl 28, pp.681-695, 2008.
DOI : 10.1177/0091270008316886

D. Ternant, A. Aubourg, C. Magdelaine-beuzelin, D. Degenne, H. Watier et al., Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients, Therapeutic Drug Monitoring, vol.PAP, pp.523-529, 2008.
DOI : 10.1097/FTD.0b013e318180e300

URL : https://hal.archives-ouvertes.fr/hal-00616549